Themes
Business
Talent
At the park
Communities
Jobs & internships
Events
News
Contact
Congratulations to the team at Alesta Therapeutics on raising an impressive €65 million in their Series A financing! Led by Frazier Life Sciences and Droia Ventures, this round will push their work in rare disease therapies to new levels.
Their lead program, ALE1, targets hypophosphatasia (HPP), a rare genetic disorder, with plans to enter clinical trials in 2025. With a second program addressing Charcot-Marie-Tooth (CMT), Alesta is on a mission to transform patient care in underserved areas.
This milestone shows how innovative science, dedicated leadership, and collaboration with global experts lead to impactful results.
We’re excited to see how this funding accelerates their work to deliver life-changing therapies. And we’re proud to see a company in our community thrive on its journey to make a difference in patients’ lives globally.
Huge congrats to the Alesta team and their partners for this incredible achievement!
Read the full press release here
A new research collaboration between TNO, Logick Energetics B.V., and InnoSer has officially kicked off at Leiden Bio Science Park, supported by a TKI-LSH grant. The partners...
The Faculty of Science at Leiden University is offering a new opportunity for professionals to deepen their knowledge of data-driven decision-making, complex systems, and...
𝗪𝗵𝗮𝘁 𝗵𝗮𝗽𝗽𝗲𝗻𝘀 𝘄𝗵𝗲𝗻 𝗺𝗼𝗿𝗲 𝘁𝗵𝗮𝗻 𝟭𝟱 𝘀𝗰𝗶𝗲𝗻𝗰𝗲 𝗮𝗻𝗱 𝗯𝗶𝗼𝘁𝗲𝗰𝗵 𝗼𝗿𝗴𝗮𝗻𝗶𝘀𝗮𝘁𝗶𝗼𝗻𝘀 𝗼𝗽𝗲𝗻 𝘁𝗵𝗲𝗶𝗿 𝗱𝗼𝗼𝗿𝘀 𝘁𝗼 𝘁𝗵𝗲 𝗽𝘂𝗯𝗹𝗶𝗰? You get an Open Day that brings together over 2,400 visitors, families, students,...